Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. E6005
2. Methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate
3. Rvt-501
1. Lotamilast
2. 947620-48-6
3. E6005
4. E-6005
5. Rvt-501
6. Lotamilast [usan]
7. To043kkb9c
8. Methyl 4-({3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl}carbamoyl)benzoate
9. (methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl(amino)carbonyl)benzoate
10. Methyl 4-[[3-[6,7-dimethoxy-2-(methylamino)quinazolin-4-yl]phenyl]carbamoyl]benzoate
11. Benzoic Acid, 4-(((3-(6,7-dimethoxy-2-(methylamino)-4-quinazolinyl)phenyl)amino)carbonyl)-, Methyl Ester
12. Unii-to043kkb9c
13. Lotamilast [inn]
14. Lotamilast (usan/inn)
15. Lotamilast [who-dd]
16. Schembl369445
17. Chembl3989967
18. Rvt 501
19. Bcp25249
20. Ex-a1382
21. Xmb62048
22. Bdbm50559709
23. Mfcd28502071
24. Zinc113676839
25. Cs-7517
26. Db12776
27. Sb16962
28. Ac-35466
29. As-52366
30. Hy-12740
31. D11305
32. P14967
33. A901684
34. Q27290049
| Molecular Weight | 472.5 g/mol |
|---|---|
| Molecular Formula | C26H24N4O5 |
| XLogP3 | 4.2 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 8 |
| Exact Mass | 472.17466988 g/mol |
| Monoisotopic Mass | 472.17466988 g/mol |
| Topological Polar Surface Area | 112 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 716 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Digital Content 
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Lotamilast manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Lotamilast, including repackagers and relabelers. The FDA regulates Lotamilast manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Lotamilast API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Lotamilast supplier is an individual or a company that provides Lotamilast active pharmaceutical ingredient (API) or Lotamilast finished formulations upon request. The Lotamilast suppliers may include Lotamilast API manufacturers, exporters, distributors and traders.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Lotamilast as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Lotamilast API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Lotamilast as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Lotamilast and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Lotamilast NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Lotamilast suppliers with NDC on PharmaCompass.
Lotamilast Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Lotamilast GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Lotamilast GMP manufacturer or Lotamilast GMP API supplier for your needs.
A Lotamilast CoA (Certificate of Analysis) is a formal document that attests to Lotamilast's compliance with Lotamilast specifications and serves as a tool for batch-level quality control.
Lotamilast CoA mostly includes findings from lab analyses of a specific batch. For each Lotamilast CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Lotamilast may be tested according to a variety of international standards, such as European Pharmacopoeia (Lotamilast EP), Lotamilast JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Lotamilast USP).
LOOKING FOR A SUPPLIER?
